Corvus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CRVS Corvus Pharmaceuticals Inc
ALTR Altair Engineering Inc
CVX Chevron Corp
ASCB ASPAC II Acquisition Corp
STRS Stratus Properties Inc
ESMC Escalon Medical Corp
ATO Atmos Energy Corp
LVS Las Vegas Sands Corp
HUBB Hubbell Inc
PM Philip Morris International Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Corvus Pharmaceuticals, Inc. is an immunology biopharmaceutical company focused on developing drugs and antibodies that target the critical cellular elements of the immune system. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression, and CPI-935, Adenosine A2B Receptor Antagonist.

Closing Price
$0.8185
Day's Change
0.0352 (4.49%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.8446
Day's Low
0.77
Volume
(Light)
Volume:
137,578

10-day average volume:
212,482
137,578

Display:

Providers:

UpdateCancel
4 providers

No article found.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.